CGEM

Company Overview — What Does Cullinan Therapeutics, Inc. Do?

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Cullinan Therapeutics, Inc. (CGEM) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Nadim Ahmed and employs approximately 30 people. With a market capitalization of $844M, CGEM is one of the notable companies in the Healthcare sector.

Cullinan Therapeutics, Inc. (CGEM) Stock Rating — Reduce (April 2026)

As of April 2026, Cullinan Therapeutics, Inc. receives a Reduce rating with a composite score of 36.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CGEM ranks #2,042 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cullinan Therapeutics, Inc. ranks #223 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CGEM Stock Price and 52-Week Range

Cullinan Therapeutics, Inc. (CGEM) currently trades at $14.54. The stock lost $0.67 (4.4%) in the most recent trading session. The 52-week high for CGEM is $16.74, which means the stock is currently trading -13.1% from its annual peak. The 52-week low is $5.68, putting the stock 156.0% above its annual trough. Recent trading volume was 388K shares, suggesting relatively thin trading activity.

Is CGEM Overvalued or Undervalued? — Valuation Analysis

Cullinan Therapeutics, Inc. (CGEM) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.20x, versus the sector average of 2.75x.

At current multiples, Cullinan Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cullinan Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Cullinan Therapeutics, Inc. (CGEM) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -51.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -46.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CGEM Debt, Balance Sheet, and Financial Health

Cullinan Therapeutics, Inc. has a debt-to-equity ratio of 10.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.25x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $103M.

CGEM has a beta of 0.96, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Cullinan Therapeutics, Inc. is 43/100, reflecting average volatility within the normal range for its sector.

Cullinan Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cullinan Therapeutics, Inc. reported revenue of $0. Net income for the quarter was $-210M. Operating income came in at $-235M.

In FY 2025, Cullinan Therapeutics, Inc. reported revenue of $0. Net income for the quarter was $-220M. Operating income came in at $-242M.

In Q3 2025, Cullinan Therapeutics, Inc. reported revenue of $0. Net income for the quarter was $-51M. Operating income came in at $-56M.

In Q2 2025, Cullinan Therapeutics, Inc. reported revenue of $0. Net income for the quarter was $-70M. Operating income came in at $-76M.

Over the past 8 quarters, Cullinan Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CGEM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CGEM Dividend Yield and Income Analysis

Cullinan Therapeutics, Inc. (CGEM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CGEM Momentum and Technical Analysis Profile

Cullinan Therapeutics, Inc. (CGEM) has a momentum factor score of 73/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CGEM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cullinan Therapeutics, Inc. (CGEM) ranks #223 out of 838 stocks based on the Blank Capital composite score. This places CGEM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CGEM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CGEM vs S&P 500 (SPY) comparison to assess how Cullinan Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

CGEM Next Earnings Date

No upcoming earnings date has been announced for Cullinan Therapeutics, Inc. (CGEM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CGEM? — Investment Thesis Summary

The quantitative profile for Cullinan Therapeutics, Inc. suggests caution. The quality score of 28/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Price momentum is positive at 73/100, suggesting the trend favors buyers.

In summary, Cullinan Therapeutics, Inc. (CGEM) earns a Reduce rating with a composite score of 36.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CGEM stock.

Related Resources for CGEM Investors

Explore more research and tools: CGEM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CGEM head-to-head with peers: CGEM vs AZN, CGEM vs SLGL, CGEM vs VMD.